Evidence map›Paper›PMID 25125464›Full record

ArticleJournal of Alzheimer's disease : JAD2015

Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.

Shannon N Campbell, Cheng Zhang, Louise Monte, Allyson D Roe, Kenner C Rice, Yvette Taché, Eliezer Masliah, Robert A Rissman

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 48 citations in OpenAlex.

  1. Stress, stress systems, and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  2. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Alzheimer's Disease and Its Potential Alternative Therapeutics.Journal of Alzheimer's disease & Parkinsonism · 2019
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shannon N CampbellDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Cheng ZhangDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Louise MonteDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Allyson D RoeDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
Kenner C RiceChemical Biology Research Branch, National Institutes on Drug Abuse and Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Yvette TachéCenter for Neurobiology of Stress and Women's Health, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA CURE Digestive Diseases Research Center and Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System Los Angeles, CA, USA.
Eliezer MasliahDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA Department of Pathology, University of California, San Diego, La Jolla, CA, USA.
Robert A RissmanDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
University of California, San Diego · USNational Institute on Alcohol Abuse and Alcoholism · USUniversity of California, Los Angeles · US

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GALASKO, DOUGLAS R · 1985 to 2018
$55.4M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Project-002P30NS076411 · NINDS · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI LIPTON, STUART A · 2011 to 2016
$4.5M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
Stress and CRF Signaling in Alzheimer?s Disease PathogenesisR01AG032755 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI RISSMAN, ROBERT, SAWCHENKO, PAUL E. · 2008 to 2012
$1.9M
Medicinal Chemistry of Drugs Acting on CRH ReceptorsZIADA000528 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2018
$1.8M
Intramural NIH HHSNIA NIH HHS AG005131NIA NIH HHS AG032755NIA NIH HHS P50 AG005131NIA NIH HHS R01 AG018440NIA NIH HHS R01 AG032755NIA NIH HHS R37 AG018440NIA NIH HHS U19 AG010483NIDDK NIH HHS P30 DK041301NINDS NIH HHS P30 NS076411
6 · The paper itself

Abstract

Clinical and basic science research suggests that stress and/or changes in central stress signaling intermediates may be involved in Alzheimer's disease (AD) pathogenesis. Although the links between stress and AD remain unsettled, data from our group and others have established that stress exposure in rodents may confer susceptibility to AD pathology by inducing hippocampal tau phosphorylation (tau-P). Work in our laboratory has shown that stress-induced tau-P requires activation of the type-1 corticotropin-releasing factor receptor (CRFR1). CRF overexpressing (CRF-OE) mice are a model of chronic stress that display cognitive impairment at 9-10 month of age. In this study we used 6-7 month old CRF-OE mice to examine whether sustained exposure to CRF and stress steroids would impact hippocampal tau-P and kinase activity in the presence or absence of the CRFR1-specific antagonist, R121919, given daily for 30 days. CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK). Examination of hippocampal extracts from CRF-OE mice at the ultrastructural level revealed negatively stained round/globular aggregates that were positively labeled by PHF-1. These data suggest critical roles for CRF and CRFR1 in tau-P and aggregation and may have implications for the development of AD cognitive decline.

Indexed as

AnimalsCorticotropin-Releasing HormoneCRF Receptor, Type 1HippocampusMiceMice, TransgenicPhosphorylationProtein Aggregation, PathologicalReceptors, Corticotropin-Releasing Hormonetau ProteinsCorticotropin-Releasing HormoneCRF Receptor, Type 1Receptors, Corticotropin-Releasing Hormonetau ProteinsAlzheimer's diseasecorticotropin-releasing factor (CRF)corticotropin-releasing factor receptor (CRFR)electron microscopyhippocampusimmunohistochemistrystresstau phosphorylation (tau-P)western blot

Identifiers

PMID25125464
PMCPMC4258165
OpenAlexW1193091174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.